Dimenhydrinate

Generic Name
Dimenhydrinate
Brand Names
Dramamine, Driminate, Gravol
Drug Type
Small Molecule
Chemical Formula
C24H28ClN5O3
CAS Number
523-87-5
Unique Ingredient Identifier
JB937PER5C
Background

Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery.
...

Indication

Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.

Associated Conditions
Dizziness, Labyrinthine disorder, Menière's Disease, Morning Sickness, Motion Sickness, Nausea, Nausea and vomiting, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Vertigo, Vomiting
Associated Therapies
-

The Effect of Dimenhydrinate on Postoperative Nausea and Vomiting After Abdominal Hysterectomy: Randomized-controlled Trial

Not Applicable
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-05-01
Last Posted Date
2024-05-01
Lead Sponsor
Preeyaporn Jirakittidul
Target Recruit Count
160
Registration Number
NCT06395064

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

First Posted Date
2020-10-28
Last Posted Date
2024-10-08
Lead Sponsor
Jennifer Holder-Murray
Target Recruit Count
2500
Registration Number
NCT04606264
Locations
🇺🇸

UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

UPMC Presbyterian, Pittsburgh, Pennsylvania, United States

🇺🇸

UPMC Passavant, Pittsburgh, Pennsylvania, United States

Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo

First Posted Date
2014-10-01
Last Posted Date
2014-10-01
Lead Sponsor
Pamukkale University
Target Recruit Count
200
Registration Number
NCT02253524

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-04-14
Last Posted Date
2023-02-08
Lead Sponsor
Apsen Farmaceutica S.A.
Target Recruit Count
292
Registration Number
NCT02112578
Locations
🇧🇷

Clinica de Alergia MarttiAntila, Sorocaba, São Paulo, Brazil

🇧🇷

ISPEM, São José dos Campos, São Paulo, Brazil

🇧🇷

Clinilive, Maringá, Paraná, Brazil

and more 4 locations

Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy

First Posted Date
2012-03-05
Last Posted Date
2012-07-31
Lead Sponsor
Prince of Songkla University
Target Recruit Count
340
Registration Number
NCT01543945
Locations
🇹🇭

Anesthesiology Department, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-11-17
Last Posted Date
2010-03-29
Lead Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Target Recruit Count
149
Registration Number
NCT00791960
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis

Phase 4
Completed
Conditions
Interventions
First Posted Date
2005-07-28
Last Posted Date
2012-03-01
Lead Sponsor
St. Justine's Hospital
Target Recruit Count
150
Registration Number
NCT00124787
Locations
🇨🇦

Ste-Justine Hospital, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath